Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
Cancer Biother Radiopharm
; 15(5): 431-45, 2000 Oct.
Article
en En
| MEDLINE
| ID: mdl-11155816
ABSTRACT
Translational research supports the use of radiolabeled antiferritin for recurrent Hodgkin's disease. A 60% tumor response rate is obtained after treatment of out-patients with polyclonal radiolabeled antiferritin. Hodgkin's disease masses shrink after radiolabeled antiferritin treatment due to the radiation delivered by the radioimmunoconjugate. Unlabeled antiferritin does not cause tumor shrinkage. Hodgkin's disease provides unique opportunities for the development and optimization of radiolabeled immunoglobulin therapy for other malignancies as well. Radiolabeled Immunoglobulin Therapy is a useful addition to the cancer treatment armamentarium due to its high therapeutic ratio high tumor response rates with side effects limited to hematopoetic tissues.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Radioisótopos de Itrio
/
Inmunoglobulinas
/
Enfermedad de Hodgkin
/
Radioisótopos de Indio
/
Inmunoconjugados
/
Ferritinas
/
Anticuerpos Monoclonales
/
Proteínas de Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Cancer Biother Radiopharm
Asunto de la revista:
FARMACIA
/
FARMACOLOGIA
/
NEOPLASIAS
/
TERAPEUTICA
Año:
2000
Tipo del documento:
Article
País de afiliación:
Estados Unidos